Patient data
| Patient . | Age . | Diagnosis . | Staining intensity . | MVD . | SUV . | T/B . |
|---|---|---|---|---|---|---|
| 1 | 64 | Glioblastoma multiforme, periphery | I tumor cells + vessels | 2.3 | 2.2 | 1.5 |
| Glioblastoma multiforme, center | 0 | 0 | 0.5 | 0.3 | ||
| 2 | 74 | Malignant fibrous histiocytoma | II tumor cells + vessels | 7.7 | 3.2 | 3.1 |
| Muscle adjacent to tumor | 0 | 0 | 0.6 | 0.6 | ||
| 3 | 57 | Glioblastoma multiforme | I tumor cells + vessels | 0.7 | 1.5 | 1.7 |
| 4 | 33 | SCC oral cavity | I vessels | 2.0 | 3.0 | 2.5 |
| Benign lymph node | 0 | 0 | 0.4 | 0.3 | ||
| 5 | 50 | lymph node metastasis SCC soft palate | II vessels | 3.3 | 2.9 | 3.1 |
| 6 | 67 | neurinoma | I vessels | 1.3 | 1.5 | 1.3 |
| 7 | 84 | Liposarcoma G1 | 0 | 0.7 | 0.4 | 0.2 |
| 8 | 66 | Melanoma, subcutaneous metastasis | I tumor cells | 0 | 2.2 | 1.7 |
| Melanoma, subcutaneous metastasis | I tumor cells | 0 | 2.5 | 1.9 | ||
| 9 | 54 | Breast cancer | II tumor cells + vessels | 2.3 | 3.1 | 2.6 |
| 10 | 41 | Osteosarcoma | III tumor cells + vessels | 3.7 | 3.3 | 3.9 |
| 11 | 56 | Malignant fibrous histiocytoma | I tumor cells + vessels | 1.3 | 2.9 | 2.5 |
| 12 | 51 | Liposarcoma G1, periphery | I vessels | 0.7 | 1.5 | 1.1 |
| Liposarcoma G1, center | 0 | 0 | 0.3 | 0.2 | ||
| 13 | 35 | Osteosarcoma, periphery | III tumor cells + vessels | 6.7 | 3.8 | 3.7 |
| Osteosarcoma, periphery | III tumor cells + vessels | 9 | 4.0 | 3.8 | ||
| 14 | 55 | Osseous metastasis (RCC) | II tumor cells + vessels | 9 | 3.0 | 2.0 |
| 15 | 75 | Soft tissue sarcoma | III tumor cells + vessels | 31.7 | 7.0 | 7.1 |
| Inflammation | II vessels | 3.3 | 2.0 | 2.0 | ||
| 16 | 36 | Melanoma, lymph node metastasis | III tumor cells | 9 | 6.0 | 5.3 |
| 17 | 89 | (Melanoma) chronic inflammation | I vessels | 4.0 | 2.3 | 1.7 |
| 18 | 31 | Pigmented villonodular synovitis | III vessels | 23.7 | 3.8 | 5.4 |
| 19 | 44 | Melanoma, lymph node metastasis | III tumor cells | 4 | 4.0 | 3.6 |
| Patient . | Age . | Diagnosis . | Staining intensity . | MVD . | SUV . | T/B . |
|---|---|---|---|---|---|---|
| 1 | 64 | Glioblastoma multiforme, periphery | I tumor cells + vessels | 2.3 | 2.2 | 1.5 |
| Glioblastoma multiforme, center | 0 | 0 | 0.5 | 0.3 | ||
| 2 | 74 | Malignant fibrous histiocytoma | II tumor cells + vessels | 7.7 | 3.2 | 3.1 |
| Muscle adjacent to tumor | 0 | 0 | 0.6 | 0.6 | ||
| 3 | 57 | Glioblastoma multiforme | I tumor cells + vessels | 0.7 | 1.5 | 1.7 |
| 4 | 33 | SCC oral cavity | I vessels | 2.0 | 3.0 | 2.5 |
| Benign lymph node | 0 | 0 | 0.4 | 0.3 | ||
| 5 | 50 | lymph node metastasis SCC soft palate | II vessels | 3.3 | 2.9 | 3.1 |
| 6 | 67 | neurinoma | I vessels | 1.3 | 1.5 | 1.3 |
| 7 | 84 | Liposarcoma G1 | 0 | 0.7 | 0.4 | 0.2 |
| 8 | 66 | Melanoma, subcutaneous metastasis | I tumor cells | 0 | 2.2 | 1.7 |
| Melanoma, subcutaneous metastasis | I tumor cells | 0 | 2.5 | 1.9 | ||
| 9 | 54 | Breast cancer | II tumor cells + vessels | 2.3 | 3.1 | 2.6 |
| 10 | 41 | Osteosarcoma | III tumor cells + vessels | 3.7 | 3.3 | 3.9 |
| 11 | 56 | Malignant fibrous histiocytoma | I tumor cells + vessels | 1.3 | 2.9 | 2.5 |
| 12 | 51 | Liposarcoma G1, periphery | I vessels | 0.7 | 1.5 | 1.1 |
| Liposarcoma G1, center | 0 | 0 | 0.3 | 0.2 | ||
| 13 | 35 | Osteosarcoma, periphery | III tumor cells + vessels | 6.7 | 3.8 | 3.7 |
| Osteosarcoma, periphery | III tumor cells + vessels | 9 | 4.0 | 3.8 | ||
| 14 | 55 | Osseous metastasis (RCC) | II tumor cells + vessels | 9 | 3.0 | 2.0 |
| 15 | 75 | Soft tissue sarcoma | III tumor cells + vessels | 31.7 | 7.0 | 7.1 |
| Inflammation | II vessels | 3.3 | 2.0 | 2.0 | ||
| 16 | 36 | Melanoma, lymph node metastasis | III tumor cells | 9 | 6.0 | 5.3 |
| 17 | 89 | (Melanoma) chronic inflammation | I vessels | 4.0 | 2.3 | 1.7 |
| 18 | 31 | Pigmented villonodular synovitis | III vessels | 23.7 | 3.8 | 5.4 |
| 19 | 44 | Melanoma, lymph node metastasis | III tumor cells | 4 | 4.0 | 3.6 |
NOTE: Staining intensity of immunohistochemistry of αvβ3 expression.
Abbreviations: SCC, squamous cell carcinoma; RCC, renal cell carcinoma; G, tumor grading.